Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 15Lymphoid 15Plasma cell 1Dermatologic 1Classical hematology 1

Conditions

Melanoma 3139Skin Neoplasms 554Lymphoma, T-Cell, Cutaneous 543Carcinoma, Non-Small-Cell Lung 421Neoplasms 388Mycosis Fungoides 369Breast Neoplasms 364Carcinoma, Basal Cell 359Keratosis, Actinic 335Sezary Syndrome 331Lymphoma, Non-Hodgkin 312Carcinoma, Renal Cell 308Neoplasm Metastasis 304Lymphoma 299Leukemia, Lymphocytic, Chronic, B-Cell 292Lymphoma, Large B-Cell, Diffuse 287Lymphoma, Follicular 286Hodgkin Disease 275Uveal Melanoma 274Lymphoma, B-Cell, Marginal Zone 273Lymphoma, Mantle-Cell 272Precursor Cell Lymphoblastic Leukemia-Lymphoma 271Burkitt Lymphoma 258Lymphoma, Large-Cell, Immunoblastic 248Lung Neoplasms 236Colorectal Neoplasms 232Ovarian Neoplasms 214Lymphoma, Large-Cell, Anaplastic 206Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 203Multiple Myeloma 199

Interventions

letermovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Prolymphocytic, B-Cell × Dermatologic × Clear all
NCT04312841 2025-02-28

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
6 enrolled 11 charts
DermatologicLymphoidOther hematologic neoplasm

Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡